Institute of Hematology & Blood Diseases Hospital, China: Leukemia, Lymphoid trials

The registry lists 16 Leukemia, Lymphoid studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 9 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 5Phase 2 9No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic LeukemiaRecruitingNCT07019766
• Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALLNot yet recruitingNCT06658925Phase 2
• Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingNCT06608732Phase 2
• Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic LeukemiaRecruitingNCT06608342Phase 2
• the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT06461091
• Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingNCT06427330Phase 2
• MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
• A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingNCT06087419Phase 1/2
• A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedNCT05676710Phase 1
• Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
• A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Phase 1
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT04034446Early Phase 1
• CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaCompletedNCT02975687Phase 1